231 related articles for article (PubMed ID: 20498245)
1. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.
Gourishankar S; Houde I; Keown PA; Landsberg D; Cardella CJ; Barama AA; Dandavino R; Shoker A; Pirc L; Wrobel MM; Kiberd BA
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1282-9. PubMed ID: 20498245
[TBL] [Abstract][Full Text] [Related]
2. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
3. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
[TBL] [Abstract][Full Text] [Related]
7. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
8. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial.
van Gelder T; Silva HT; de Fijter JW; Budde K; Kuypers D; Tyden G; Lohmus A; Sommerer C; Hartmann A; Le Meur Y; Oellerich M; Holt DW; Tönshoff B; Keown P; Campbell S; Mamelok RD
Transplantation; 2008 Oct; 86(8):1043-51. PubMed ID: 18946341
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
Pons B; Delavenne X; Mehdi M; Maillard N; Sauron C; Berthoux F; Alamartine E; Basset T; Mariat C
Clin Nephrol; 2012 Jun; 77(6):425-31. PubMed ID: 22595383
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.
van Gelder T; Hilbrands LB; Vanrenterghem Y; Weimar W; de Fijter JW; Squifflet JP; Hené RJ; Verpooten GA; Navarro MT; Hale MD; Nicholls AJ
Transplantation; 1999 Jul; 68(2):261-6. PubMed ID: 10440399
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
[TBL] [Abstract][Full Text] [Related]
12. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
[TBL] [Abstract][Full Text] [Related]
13. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
[TBL] [Abstract][Full Text] [Related]
14. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
van Gelder T; Silva HT; de Fijter H; Budde K; Kuypers D; Mamelok RD; Armstrong VW; Oellerich M
Ther Drug Monit; 2011 Apr; 33(2):155-64. PubMed ID: 21383657
[TBL] [Abstract][Full Text] [Related]
15. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
17. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
18. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
20. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]